<DOC>
	<DOCNO>NCT00327730</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Eperisone HCl treatment Acute Musculoskeletal spasm associate Low-Back Pain .</brief_summary>
	<brief_title>Evaluation Eperisone HCl Treatment Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind , Randomised , Placebo Controlled Clinical Trial</brief_title>
	<detailed_description>This multi-center trial , conduct total 240 patient ( 120 patient treatment group ) . Patients attend out-patient set traumatology orthopedic department study center screen lumbar pain spasm clinical radiological examination inclusion . In study , plan enroll total 240 patient 120 patient group . The total duration treatment 14 day . Patients screen baseline parameter randomize , per predetermine randomization schedule , two group . Patients treat either Eperisone-HCl ( Myonal ) placebo period 14 day . After baseline-screening visit ( Day 1 ) , patient would ask follow day 3 , day 7 , day 14 . During visit , complete general examination clinical evaluation efficacy parameter would do . Adverse event would monitor study period would record Case Report Form ( CRF ) . At end treatment , Global Assessment Response Therapy Physicians Patients ( PGART ) would do efficacy tolerability separately .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Muscle Cramp</mesh_term>
	<mesh_term>Eperisone</mesh_term>
	<criteria>1 . Patients either sex 18 60 year age . 2 . Patients confirm diagnosis Acute Musculoskeletal spasm Low Back Pain due : Spondylosis deformans Prolapsed Intervertebral Disc ( PID ) Muscle sprain spasms 3 . Patients willing take medication direct willing come followup . 4 . Patients willing comply protocol requirement . 5 . Patients willing give write informed consent . 1 . Patients associated spasm condition like : Muscle sprain spasms hip/knee/ankle Traumatic pain spasms Cervical Spondylitis Pain &amp; spasm associate fracture bone . 2 . Patients take form skeletal muscle relaxant previous 7 day . 3 . Patients hypersensitivity ingredient test &amp; control formulation . 4 . Pregnant/Lactating woman woman child bear potential follow adequate contraceptive measure . 5 . Patients unwilling unable comply study procedure . 6 . Patients history severe acute infection , major surgery trauma , severe metabolic , endocrine electrolyte disturbance seizures precede 8 week . 7 . Patients severe renal insufficiency define creatinine value 2.5 mg/dl . 8 . Patients severe hepatic insufficiency define SGOT SGPT value equal high threefold normal value respective laboratory reference value . 9 . Patients follow disorder : Renal failure Bulimia Hypo Hyperthyroidism Nephrotic syndrome Anorexia nervosa Biliary obstruction Severe cardiac dysfunction . 10 . Patients uncontrolled diabetes mellitus , metabolic endocrine disorder . 11 . Patients receive treatment investigational drug precede 4 week . 12 . Patients likely noncompliant ( alcohol , smoke drug abuser ) . 13 . Any condition , opinion investigator , justify patient 's inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Muscle</keyword>
	<keyword>Spasm</keyword>
	<keyword>Back</keyword>
	<keyword>Pain</keyword>
</DOC>